“Emergent BioSolutions Inc. said Tuesday it was awarded
a contract for its smallpox vaccine from the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years. The contract specifically supports the continued supply of Emergent’s ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS)…” (Flax, 9/3).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.